Clinical Trial Update: Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating cetuximab with gemcitabine and carboplatin in stage IV non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Cetuximab (cetuximab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Stage IV Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED